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Abstract
Previous studies have established that scores on Major Depressive Disorder scales are correlated with measures of
impairment of psychosocial functioning. It remains unclear, however, whether individual depressive symptoms vary in their
effect on impairment, and if so, what the magnitude of these differences might be. We analyzed data from 3,703 depressed
outpatients in the first treatment stage of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.
Participants reported on the severity of 14 depressive symptoms, and stated to what degree their depression impaired
psychosocial functioning (in general, and in the five domains work, home management, social activities, private activities,
and close relationships). We tested whether symptoms differed in their associations with impairment, estimated unique
shared variances of each symptom with impairment to assess the degree of difference, and examined whether symptoms
had variable impacts across impairment domains. Our results show that symptoms varied substantially in their associations
with impairment, and contributed to the total explained variance in a range from 0.7% (hypersomnia) to 20.9% (sad mood).
Furthermore, symptoms had significantly different impacts on the five impairment domains. Overall, sad mood and
concentration problems had the highest unique associations with impairment and were among the most debilitating
symptoms in all five domains. Our findings are in line with a growing chorus of voices suggesting that symptom sum-scores
obfuscate relevant differences between depressed patients and that substantial rewards will come from close attention to
individual depression symptoms.
Citation: Fried EI, Nesse RM (2014) The Impact of Individual Depressive Symptoms on Impairment of Psychosocial Functioning. PLoS ONE 9(2): e90311.
doi:10.1371/journal.pone.0090311
Editor: Qiyong Gong, West China Hospital of Sichuan University, China
Received October 14, 2013; Accepted January 30, 2014; Published February 28, 2014
Copyright:  2014 Fried, Nesse. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The STAR*D study was supported by NIMH Contract # N01MH90003 to the University of Texas Southwestern Medical Center (http://www.nimh.nih.
gov). The ClinicalTrials.gov identifier is NCT00021528. This manuscript reflects the views of the authors and may not reflect the opinions or views of the STAR*D
study investigators or the NIMH. Mr. Fried is supported by fellowships from the Cluster of Excellence ‘‘Languages of Emotion’’ (grant no. EXC302, http://www.loe.
fu-berlin.de) and the German Research Foundation (www.dfg.de). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: eiko.fried@gmail.com
Introduction
About 60% of individuals who meet criteria for Major
Depressive Disorder (MDD) as defined by the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5) [1] report severe
or very severe impairment of functioning [2]. Impairment
associated with depression is long-lasting [3] and equal or greater
than impairment caused by other common, chronic medical
conditions such as diabetes, hypertension, heart attack, and
congestive heart failure [4,5]. Moreover, depression impairs
functioning in various domains such as home life, workplace,
friends, and family [6,7] – severely compromising the capacity for
self-care and independent living in many cases.
A recent review found moderate correlations between scores on
various screening instruments for depression and measures of
impairment [8]. It has been unclear, however, whether certain
symptoms are more impairing than others, and if so, what the
magnitude of these differences might be. This question is highly
relevant because of large differences in the symptoms experienced
by patients diagnosed with MDD.
Qualifying for a diagnosis of MDD requires experiencing at
least five of the nine DSM symptomatic criteria, among which at
least one has to be either sad mood or loss of interest, for at least 2
weeks. Four symptoms are compound symptoms comprised by
different subsymptoms (feelings of worthlessness or inappropriate
guilt) or opposite subsymptoms (insomnia or hypersomnia,
psychomotor agitation or retardation, weight loss or weight gain),
leading to 1,497 unique symptom profiles that all qualify for the
same diagnosis [9], including profiles that do not have a single
symptom in common. Considerable symptom variability has been
reported across individuals [10–12] and within individuals across
time [13,14].
Specific depressive symptoms have received comparably little
attention because they are assumed to be diagnostically inter-
changeable indicators of a common diagnosis. This assumption of
symptom equivalence [15] goes hand in hand with the concep-
tualization of depression within the framework of reflective latent
variable modeling [16,17]: variation in the latent disorder
depression causes variation of the observable symptoms. Depression
is viewed as the common cause for diverse symptoms such as
insomnia, psychomotor agitation, or loss of interest – which is the
reason why symptoms are measured in order to assess depression.
Since all symptoms indicate the same latent disease, only the
number of symptoms is relevant, not their natures. The notion that
different symptoms are diagnostically equivalent justifies the
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common practice of summing the number of symptoms to reflect
depression severity.
However, several authors have suggested that there are
substantial benefits to analyzing depressive symptoms individually
[15,18–20]. This is supported by evidence showing that symptoms
differ from each other in their associations with demographic
variables, personality traits, lifetime comorbidities, and risk factors
[15,21], and it has been established that specific stressful life events
are predictive of distinct MDD symptom profiles [22–25].
Furthermore, particular gene polymorphisms are associated with
specific depressive symptoms [26,27], and a recent study of 7,500
twins concluded that the DSM symptomatic criteria for depression
do not reflect a single underlying genetic factor [28].
We are aware of only a single previous study that explored
concurrent effects of individual depressive symptoms on impair-
ment of psychosocial functioning [29]. In this analysis of a general
population sample, six DSM-III [30] symptoms were significantly
associated with impairment (depressed mood, dysthymia, cognitive
difficulties, suicidal ideation, fatigue, and sexual disinterest).
The present study extends the previous report [29] in four
important aspects: (1) we examine the differential impact of
symptoms on impairment in a large and highly representative
sample of 3,703 depressed patients; (2) we use the updated DSM-5
criterion symptoms; (3) we investigate subsymptoms (e.g., psycho-
motor agitation and psychomotor retardation) instead of com-
pound symptoms (e.g., psychomotor problems); (4) lastly, we test
whether symptoms vary in their impacts across five impairment
domains.
Materials and Methods
Study description
Data from the first treatment stage (level 1) of the NIH-
supported ‘‘Sequenced Treatment Alternatives to Relieve Depres-
sion’’ (STAR*D) study [31,32] were analyzed for this report. Data
can be obtained from the NIMH and were provided to the authors
under terms of an NIHM Data Use Certificate that protects
confidentiality; dataset version 3 was used. STAR*D was a
multisite randomized clinical trial conducted in the USA to
investigate which of several treatment options would be most
effective for nonpsychotic MDD outpatients; 4,041 patients were
enrolled into the first treatment stage, in which all participants
received citalopram, a selective serotonin reuptake inhibitor
(SSRI) antidepressant. Outcome data were obtained via telephone
interviews that were conducted either by interviewers, or by an
interactive voice response system (IVR). STAR*D was approved
and monitored by the institutional review boards at each of the 14
participating institutions, a national coordinating center, a data
coordinating center, and the data safety and monitoring board at
the NIMH. All participants provided written informed consent at
study entry. Detailed information about design, methods, exclu-
sion criteria, and the rationale of STAR*D are described
elsewhere [31,32].
Participants
STAR*D used relatively inclusive selection criteria in order to
obtain a highly representative sample of patients seeking treatment
for MDD. Participants had to be between 18 and 75 years, fulfill
DSM-IV criteria for single or recurrent nonpsychotic MDD, and
have at least moderately severe depression corresponding to a
score of at least 14 on the 17-item Hamilton Rating Scale for
Depression (HAM-D) [33]. Participants with a history of bipolar
disorder, schizophrenia, schizoaffective disorder, or psychosis were
excluded, as were patients with current anorexia, bulimia, or
primary obsessive compulsive disorder. Further exclusion criteria
were a history of intolerability to antidepressant medication, lack
of response to an adequate trial of SSRI in the current episode of
MDD, or failure to respond to 16 or more sessions of cognitive
therapy in the current episode of MDD. Our analyses are limited
to the 3,703 individuals that were assessed within the first week of
level 1 via IVR.
Outcomes measures
STAR*D used the Quick Inventory of Depressive Symptoms
(QIDS-16 [34]) to assess depressive symptoms. The QIDS-16 has
good psychometric properties [34], and the results of the IVR
version are comparable to the results produced by the self-rated
and the clinician-rated QIDS-16 [35]. The QIDS-16 assesses the
nine DSM symptom domains with 16 questions (Table 1). Each
domain yields a score between 0 and 3, 0 indicating no problems,
3 indicating severe problems. While six symptoms are measured
with single questions, the three compound symptoms (sleep problems,
psychomotor problems, appetite/weight problems) are assessed with
multiple questions. The QIDS-16 constructs these compound
symptoms by using the highest symptom score in each symptom
group, resulting in one score on each of the nine DSM criterion
symptoms. Since we were interested in individual symptoms, we
used all available items instead of symptom domains. Detailed
information for the domain appetite and weight problems was not
available, since either appetite decrease or appetite increase, and either
weight decrease or weight increase was scored. Overall, this resulted in
twelve individual symptoms plus the two compound symptoms
appetite problems and weight problems (Table 1).
The Work and Social Adjustment Scale (WSAS [36]) was used
to measure impairment of functioning. The WSAS is a simple,
reliable, and valid self-report instrument that uses Likert-scale
ratings of 5 items to assess impairment in the domains of work,
home management, social activities, private activities, and close
relationships. Each question is rated on a 0–8 Likert scale, with 0
indicating no impairment and 8 indicating very severe impair-
ment. WSAS scores below 10 are associated with subclinical
Table 1. Depressive symptoms.
QIDS-16 symptoms Shortcode
Sleep onset insomnia Early insomnia
Mid-nocturnal insomnia Middle insomnia
Early morning insomnia Late insomnia
Hypersomnia Hypersomnia
Sad Mood Sad mood
Appetite increase Appetite
Appetite decrease Appetite
Weight increase Weight
Weight decrease Weight
Problems concentrating/making decisions Concentration
Feeling worthless/self-blame Self-blame
Suicidal ideation Suicidal ideation
Loss of interest Interest loss
Energy loss/fatigability Fatigue
Psychomotor slowing Slowed
Psychomotor agitation Agitated
doi:10.1371/journal.pone.0090311.t001
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populations; scores of 10–20 are associated with significant
functional impairment, while scores above 20 suggest at least
moderately severe functional impairment (total range 0–40). The
WSAS has been used mainly in samples with mood and anxiety
disorders, and has been shown to have good internal consistency
(0.70 to 0.94) and retest-reliability (0.73), and high concurrent
validity of IVR administrations with clinician interviews (0.81 and
0.86) [37]. In STAR*D, the WSAS specifically queried partici-
pants how much their depression impaired work and social activities.
For instance, work impairment was measured via the following
item: ‘‘Because of my depression, my ability to work is impaired. 0
means not at all impaired and 8 means very severely impaired to
the point I can’t work.’’
Statistical analysis
Three analyses were performed. First, we used the 14 QIDS-16
depression symptoms to predict overall impairment as measured
by the WSAS sum-score, controlling for age and sex. We then
compared two linear regression models: in model I (heterogeneity
model), regression weights for symptoms were free to vary,
whereas model II (homogeneity model) constrained regression
weights to be equal. While model I allows for differential
impairment-symptoms associations, model II represents the
hypothesis that symptoms have equal associations with impair-
ment. A x2-test was used to compare the two models. Because
depressive symptoms are generally correlated with each other, we
performed multicollinearity diagnostics for both regression anal-
yses. The variance inflation factor (VIF) did not exceed the value
of five for any symptom, indicating no multicollinearity problems
[38].
Second, we aimed to allocate unique R2 shares (proportion of
explained variance) to each regressor to examine how much
unique variance each individual symptom shared with impair-
ment. We used the LMG metric via the R-package RELAIMPO
[39] to estimate the relative importance (RI [40–42]) of each
symptom. LMG estimates the importance of each regressor by
splitting the total R2 into one non-negative R2 share per regressor,
all of which sum to the total explained R2. This is done by
calculating the contribution of each predictor at all possible points
of entry into the model, and taking the average of those
contributions. In other words, an estimate of RI for each variable
is obtained by calculating as many regressions as there are possible
orders of regressors (in the present case, 8.761010 regressions), and
then averaging individual R2 values over all models. RI estimates
are then adjusted to sum to 100% for easier interpretation.
Confidence interval (CI) estimates of the RI coefficients, as well as
p-values indicating whether regressors differed significantly from
each other in their RI contributions (in an exploratory sense), were
obtained using the bootstrapping capabilities of the RELAIMPO
package. It is important to note that predictors with a non-
significant regression coefficient can nonetheless contribute to the
total explained variance, that is, have a non-zero LMG
contribution. This is the case when regressors are correlated with
each other and thus can indirectly influence the outcome via other
regressors [42]. Therefore, all symptoms, even those without
significant regression coefficients, were included in subsequent RI
calculations.
Third, we tested whether individual symptoms differed in their
associations across the five WSAS impairment domains work,
home management, social activities, private activities and close
relationships. We estimated two structural equation models (SEM),
using the Maximum-Likelihood Estimator. Both models contained
five linear regressions, one for each domain of impairment. In
each of these five regressions, we used the 14 depressive symptoms
as predictors of one impairment domain, controlling for age and
sex. While the first SEM allowed free estimation of all regression
coefficients (model I), the second constrained each symptom to
have equal effects (i.e. regression coefficients) across the five
impairment domains (model II). This second model represents the
hypothesis that a given symptom has similar impacts on all five
domains. We compared the models using a x2-test.
Analyses one and three were performed in MPLUS v7.0 [43],
and analysis two was estimated in R v2.13.0 [44].
Results
Of the 3,703 outpatients in the study, 2,234 (60.3%) were
female, and the mean age was 41.2 years (sd=13.2). See Table 2
for detailed demographic information.
The average impairment score was 23.52 (sd=9.29), corre-
sponding to moderately severe levels of impairment; 307 (8.3%)
individuals did not show impaired functioning, 875 (23.6%)
exhibited significant functional impairment, while 2,521 (68.1%)
reported severe functional impairment.
Homogeneity versus heterogeneity of associations
The heterogeneity model (allowing variable contributions of
symptoms to impairment) fit the data significantly better than the
homogeneity model (in which symptoms were constrained to have
the same contributions to impairment) (x2 = 394.5, df=13,
p,0.001). In the heterogeneity model, 11 of the 14 depression
symptoms as well as male sex and older age significantly predicted
impairment, explaining 40.8% of the variance (F (16,
3686) = 159.1, p,0.001) (Table 3). The heterogeneity model was
thus used for subsequent RI estimations.
Table 2. Demographic characteristics.
Category Subcategory Subjects (%)
Age #20 y 86 (2.3)
21–30 y 842 (22.7)
31–40 y 835 (22.5)
41–50 y 915 (24.7)
51–60 y 711 (19.2)
.60 y 314 (8.5)
Race White 2926 (79.0)
Black or African American 685 (18.5)
Other 92 (2.5)
Ethnicity Hispanic 452 (12.2)
Marital Status Never married 1091 (29.5)
Cohabitating with partner 310 (8.4)
Married 1238 (33.4)
Separated 245 (6.6)
Divorced 698 (18.8)
Widowed 117 (3.2)
Missing 4 (0.1)
Employment status Unemployed 1379 (37.3)
Employed 2101 (56.8)
Retired 218 (5.9)
Missing 5 (0.1)
doi:10.1371/journal.pone.0090311.t002
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Relative importance analysis
The RI estimates of all regressors, representing the allocated
individual R2 contributions of symptoms on impairment, are
displayed in Figure 1. Different symptoms had drastically different
effects on impairment, ranging from RI values of 0.7% (hypersom-
nia) to 20.9% (sad mood). Out of 91 symptom pairs, 76 (83.5%)
significantly differed in their RI contributions to impairment (all
p,0.05). RI coefficients within the two compound symptoms (sleep
problems and psychomotor problems) showed differential RI: early
insomnia (3.6%) was associated with significantly more impairment
than middle insomnia (0.8%) and hypersomnia (0.7%), while slowed
(8.7%) had a significantly larger RI estimate than agitated (2.1%)
(all p,0.05).
Are the large differences in the impact of different symptom on
disability due to the nature of symptoms, or due to their severity? If
severity, then severity differences between symptoms should
explain a large proportion of the differences of the RI estimates
(i.e. symptoms with high mean values are highly debilitating,
whereas symptoms with a low mean are associated with much less
impairment). To test this hypothesis we used a linear regression to
predict the RI of each of the 14 symptoms by its mean severity.
Symptom severity did not reach statistical significance as predictor
for symptom RI estimates (F (1,12) = 4.0, p=0.07). This implies
that RI differences are due to symptom nature, and not symptom
severity.
Impact of symptoms across impairment domains
Constraining regression weights of symptoms to be equal across
the five domains of impairment in model II significantly reduced
model fit compared to model I in which symptom contributions
were freely estimated (x2 = 299.8, df=56, p,0.001). This means
that symptoms have differential impacts across impairment
domains; these differences between the symptoms-impairment
associations across domains are visualized in Figure 2. Of the
diverse findings, three are especially noteworthy:
(1) sad mood and concentration were among the four most
debilitating symptoms in all domains;
(2) early insomnia had comparably strong effects on work
impairment, self-blame on close relationships, interest loss on social
activities, and fatigue on home management;
(3) compared to other domains, interest loss was less impairing for
the domain work, fatigue for close relationships, sad mood for home
management, and concentration for social activities as well as close
relationships.
Discussion
Overall, individual depressive symptoms have differential effects
on impairment, confirming our main hypothesis. Depressed mood,
poor concentration, fatigue and loss of interest explained a large
proportion of variance in impairment, whereas weight problems,
mid-nocturnal insomnia and hypersomnia made few unique
contributions to impairment.
Subsymptoms within symptom domains had differential effects
as well. For instance, psychomotor retardation explained roughly
four times as much variance of impairment as psychomotor
agitation. These findings highlight not only the importance of
considering the nine DSM symptoms individually, but also the
importance of considering sub-symptoms within the symptom
domains. The three most debilitating symptoms include one
affective, one cognitive and one somatic symptom, suggesting the
need to monitor all kinds of depressive symptoms instead of
focusing on only one domain or factor score. Furthermore, the two
DSM MDD core symptoms, depressed mood and interest loss,
made high contributions to explaining impairment, ranking 1
(20.7%) and 4 (13.1%) in general RI estimates. Lastly, although
some symptoms were roughly equally debilitating across different
domains of impairment, the majority of symptoms varied in their
influence across domains.
Implications
While prior research has established that symptoms are
differentially associated with demographic variables and person-
ality traits [15], risk factors [21], stressful life events [22–25], and
gene polymorphisms [26–28], our report reveals yet another
dimension of covert heterogeneity: symptoms have variable
associations with impairment of psychosocial functioning. The
broad depression diagnosis not only obscures important differenc-
es between patients and lumps individuals suffering from diverse
symptoms into the same category – two patients with the same
number of depressive symptoms may differ drastically in their
functioning levels. This concealed variability within MDD
potentially explains some of the most prominent ‘‘disappointing’’
findings portrayed in recent literature: (1) the DSM-V field trials
[45] reported a ‘‘questionable’’ inter-rater reliability of 0.28 (CI
0.20–0.35) for MDD diagnosis, lower than the majority of other
disorders (e.g., borderline personality disorder 0.54 (CI 0.43–
0.66)); (2) antidepressants are only marginally efficacious com-
pared to placebos, in spite of substantial publication and reporting
bias inflating apparent antidepressant efficacy [46]; (3) there are
few consistencies between studies investigating which brain regions
are involved in the pathophysiology of MDD [47]; (4) none of
more than half a million common genetic markers were associated
with antidepressant response in a study with 1,790 individuals
[48]; (5) lastly, no single locus reached genome-wide significance in
a genome-wide association study of 17 population-based samples
containing 34,549 subjects [49].
Table 3. Results of linear regression analysis (heterogeneity
model).
Predictors b s.e. t
Early insomnia 0.50 0.11 4.53 ***
Middle insomnia 0.01 0.15 0.08
Late insomnia 0.26 0.11 2.32 *
Hypersomnia 0.54 0.15 3.64 ***
Sad mood 2.27 0.18 12.79 ***
Appetite 0.25 0.12 2.14 *
Weight 0.13 0.11 1.17
Concentration 1.61 0.14 11.21 ***
Self-blame 0.68 0.10 6.61 ***
Suicidal ideation 0.84 0.15 5.50 ***
Interest loss 1.24 0.12 10.40 ***
Fatigue 1.08 0.12 8.78 ***
Slowed 0.84 0.14 5.93 ***
Agitated 0.02 0.13 0.13
Age 0.04 0.01 4.07 ***
Sex 20.31 0.25 21.25
b, unstandardized regression coefficient; s.e., standard error; t, t-value;
* p,0.05;
** p,0.01;
*** p,0.001.
doi:10.1371/journal.pone.0090311.t003
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The dependent variable in all studies is either a symptom sum-
score, or the categorical distinction between depressed and
healthy. In both cases, potentially important information about
symptoms is lost, and a closer examination of these symptoms is
likely to reveal important insights hidden by analyses of sum-
scores. In the present study, sleep onset insomnia had comparably
strong impact on functioning in the domain of work. It has also
been established that MDD treatment is less effective in patients
suffering from sleep problems [50], that patients with persistent
sleep problems are more than twice as likely to remain depressed
[51], and that targeting sleep problems in patients diagnosed with
MDD increases overall depression improvement [52,53]. This
example elucidates how clinically useful symptom-based ap-
proaches can be: they provide detailed information about the
nature of problems individuals suffer from, and thus offer the
opportunity to improving MDD prevention and treatment.
In addition to studying individual MDD criterion symptoms of
depression, it is important to acknowledge that the current DSM
symptoms are but a small subset of possible depression symptoms,
and were determined largely by clinical consensus instead of
empirical evidence [15,54]. Several non-DSM MDD symptoms
merit closer examination and should be assessed in future studies
of depressive symptoms, because they are highly prevalent and
associated with worse clinical outcomes. For example, studies
found anxiety and anger/irritability to be present in more than
half of the patients diagnosed with MDD [55,56], and while
remission of MDD was less likely and took longer in patients
reporting anxiety [56], anger/irritability was a clinical marker of a
more severe, chronic, and complex depressive illness [55].
Limitations
The results have to be interpreted in the light of five limitations.
First, although the impairment scale used in the STAR*D study
specifically instructed participants to rate the effects of their
depression on functioning, both depressive symptoms and
functional impairment were assessed at the same measurement
Figure 1. Relative importance coefficients of depressive symptoms on overall impairment. Relative importance coefficients of depressive
symptoms on overall impairment, including bootstrapped confidence intervals. Each value represents the unique shared variance between a
symptom and impairment, controlling for age and sex. Estimates are adjusted to sum to 100%.
doi:10.1371/journal.pone.0090311.g001
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point, so caution about causal interpretations is warranted.
Symptoms and impairment potentially reinforce each other and
are thus likely to blur, especially in individuals suffering from
chronic depression. Second, while subjects at baseline of STAR*D
were not taking antidepressant medication, many participants
reported other medical conditions for which prescribed medica-
tions might have affected symptom reports. Third, the boot-
strapped CIs for the RI estimates are fairly large for a sample of
3,703 subjects, implying a moderate amount of model uncertainty
due to the high number of regressors as well as substantial
covariation between them. Fourth, item wording may have biased
the associations of individual symptoms with impairment; in
particular, because subjects were asked to rate the impact of their
depression on impairment, sadness may be artificially inflated. To
explore this further would require alternative question wording.
Lastly, differential variability in depressive symptoms is a potential
source of biased RI estimates, because heavily skewed symptoms
with means close to the minimum and maximum are less likely to
demonstrate pronounced statistical relationships. However, symp-
tom means that ranged from 0.44 (insomnia) to 2.35 (mid-
nocturnal insomnia) did not significantly predict RI estimates, and
even the symptom with the lowest mean of 0.44 (insomnia) showed
substantial variability (sd=0.83; sd range of all other symptoms
excluding insomnia: 0.83 to 1.21).
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